GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Effective Interest Rate on Debt %

Stoke Therapeutics (Stoke Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Stoke Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Stoke Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $2.28 Mil. Therefore, Stoke Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.


Stoke Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Stoke Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Effective Interest Rate on Debt % Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - 4.13 - - -

Stoke Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stoke Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Stoke Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stoke Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Stoke Therapeutics's Effective Interest Rate on Debt % falls into.



Stoke Therapeutics Effective Interest Rate on Debt % Calculation

Stoke Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (2.359+2.062)/ 2 )
=-1  *  0/2.2105
=0.00 %

where

Stoke Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  0/( (2.498+2.062)/ 2 )
=-1  *  0/2.28
=0.00 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Stoke Therapeutics  (NAS:STOK) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Stoke Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics (Stoke Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
Executives
Barry Ticho officer: Chief Medical Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jonathan Allan officer: General Counsel & Corp Sec C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Huw M. Nash officer: COO & CBO C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Atp Life Science Ventures, L.p. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Skorpios Trust 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau officer: EVP Research & Preclinical Dev C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin director 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Stephen J Tulipano officer: CFO C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Arthur Tzianabos director C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kaye Edward M. Md director, officer: CEO 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011